Outcome of thyrotoxicosis treatment with 3 different modalities.
OBJECTIVE
To assess the efficacy of 3 different treatment modalities for thyrotoxicosis and a comparison of their cost effectiveness.


METHODS
The case records of 100 patients treated for thyrotoxicosis at King Khalid National Guard Hospital in Jeddah were reviewed, during the period January 1992 through to January 2000. Their various treatments and responses were recorded as well as their thyriometabolic status, one year following the last treatment. The treatment consisted of an average of 9 months of antithyroid medication, thyroidectomy or treatment with radioactive iodide. Cure was defined as a patient being euthyroid or hypothyroid for a minimum period of at least one year. Cost-effectiveness was calculated as the total cost of treating the patient in a specific treatment modality, divided by those who were considered to be cured.


RESULTS
For the remainder, the cost could not be definitively determined. The mean age was 41+/- 15.7 years, with female to male ratio of 6:1. Grave's disease was the underlying cause in 76% of cases, toxic multinodular goiter in 13% and toxic nodule in 1%. Ninety-one patients, who were treated with anti-thyroid medication for an average of 9 months, had a success rate of 11%. The success rate with surgery was 54.5%, while of 68 patients treated with radioactive iodide 65 (96%) were cured. Radioactive iodide was the most cost effective modality of treatment costing 1700 Saudi Riyals, followed by surgery at 40,000 Saudi Riyals. Medical treatment was the most expensive at 135,000 Saudi Riyals per cure.


CONCLUSIONS
A treatment of thyrotoxicosis with radioactive iodine is much more efficacious than medical or surgical modalities. Furthermore, it is by far the most cost effective and has no harmful effects.
Qari
F A
FA
Department of Medicine (Endocrinology & Metabolism), King Khalid Abdulaziz Medical College, PO Box 13042, Jeddah 21943, Kingdom of Saudi Arabia. karifaiza@hotmail.com
Naser
T A
TA
Hashim
I M
IM
Tevaarwerk
G J
GJ
D013956:Antithyroid Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007454:Iodides / Q000191:economics* / Q000627:therapeutic use; D007457:Iodine Radioisotopes / Q000191:economics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013965:Thyroidectomy / Q000191:economics*; D013971:Thyrotoxicosis / Q000628:therapy*; D016896:Treatment Outcome
D013956:Antithyroid Agents; D007454:Iodides; D007457:Iodine Radioisotopes